Docetaxel for Pembrolizumab‐Refractory Recurrent Basal Cell Carcinoma
The Journal of Dermatology · 2026-06 · 53 (6)
DOI: 10.1111/1346-8138.70244 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Journal of Dermatology, online erschienen am 27.03.2026. Verfasst von Yoshiki Sakai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Dermatology, Miyazaki University Graduate School of Medicine, Miyazaki, Japan.
ORCID-Profile: Yoshiki Sakai, Dai Ogata, Harutaka Seshimo, Eiji Nakano, Naoya Yamazaki, Kenjiro Namikawa
Zitieren
APA
Sakai, Y., Ogata, D., Kurisaki, M., Kase, M., Seshimo, H., Kage, Y., Nakano, E., Yamazaki, N., & Namikawa, K. (2026). Docetaxel for Pembrolizumab‐Refractory Recurrent Basal Cell Carcinoma. The Journal of Dermatology, 53(6). https://doi.org/10.1111/1346-8138.70244
Vancouver
Sakai Y, Ogata D, Kurisaki M, Kase M, Seshimo H, Kage Y, et al. Docetaxel for Pembrolizumab‐Refractory Recurrent Basal Cell Carcinoma. The Journal of Dermatology. 2026;53(6). doi:10.1111/1346-8138.70244
BibTeX
@article{Sakai2026,
author = {Sakai, Yoshiki and Ogata, Dai and Kurisaki, Michitoshi and Kase, Misaki and Seshimo, Harutaka and Kage, Yuta and Nakano, Eiji and Yamazaki, Naoya and Namikawa, Kenjiro},
title = {Docetaxel for Pembrolizumab‐Refractory Recurrent Basal Cell Carcinoma},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {6},
doi = {10.1111/1346-8138.70244}
}
EUVIMED